<?xml version="1.0" encoding="UTF-8"?>
<p>The classical HSV therapy includes daily dosing of orally administered ACV [
 <xref rid="B90-pharmaceutics-12-00171" ref-type="bibr">90</xref>] that is effective in most cases, and of course problematic in other cases, for example, in long-term use of ACV patients report resistance against the drug followed by renal injury [
 <xref rid="B91-pharmaceutics-12-00171" ref-type="bibr">91</xref>,
 <xref rid="B92-pharmaceutics-12-00171" ref-type="bibr">92</xref>]. Another issue produced by standard HSV treatment in this case for the topical form of trifluridine (TFT) and ganciclovir (ACV analog) gels, is denoted by low retention time on vaginal and corneal mucus followed by multiple doses up to 10 times [
 <xref rid="B93-pharmaceutics-12-00171" ref-type="bibr">93</xref>].
</p>
